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ABSTRACT 
Nicotine dependence and schizophrenia are two mental health disorders with remarkably high 
comorbidity. Cigarette smoking is particularly prevalent among schizophrenic patients and it 
is hypothesized to comprise a form of self-medication for relieving cognitive deficits in these 
patients. Emerging evidence suggests a role of the neurohypophysial peptide oxytocin in the 
modulation of drug addiction, as well as schizophrenia symptomology; however, the 
underlying mechanism remains unclear. Therefore, we sought to investigate the effects of 
chronic nicotine administration on oxytocin receptor (OTR) binding in the brain of a transgenic 
mouse model of schizophrenia that carries a bacterial artificial chromosome of the human 
G72/G30 locus (G72Tg). Female wild-type (WT) and heterozygous G72 transgenic CD-1 mice 
were treated with a chronic nicotine regimen (24 mg/kg/day, osmotic minipumps for 14 days) 
and quantitative autoradiographic mapping of oxytocin receptors was carried out in brains of 
these animals. OTR binding levels were higher in the cingulate cortex (CgCx), nucleus 
accumbens (Acb) and central amygdala (CeA) of saline treated G72Tg mice compared with 
WT control mice. Chronic nicotine administration reversed this upregulation in the CgCx and 
CeA. Interestingly, chronic nicotine administration induced an increase in OTR binding in the 
CeA of solely WT mice. These results indicate that nicotine administration normalizes the 
dysregulated central oxytocinergic system of this mouse model of schizophrenia and may 
contribute towards nicotine’s ability to modulate cognitive deficits which are common 
symptoms of schizophrenia.  
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INTRODUCTION 
Schizophrenia is a neuropsychiatric disorder, typically manifested during adolescence or 
early adulthood and is usually characterised by hallucinations, delusions, impaired cognitive 
function and emotional deficits (American Psychiatric Association, 2013). Impaired cognitive 
function in schizophrenia includes deficits in sensory gating (Adler et al., 1998), smooth 
pursuit eye movement (Olincy et al., 1998), working memory (Gold et al., 2006; Nuechterlein 
et al., 2008) and social cognition (Derntl & Habel, 2011).  
Converging lines of evidence indicate the presence of high comorbidity rates between 
nicotine dependence and schizophrenia; smoking prevalence among schizophrenics is 
estimated at 74-92%, compared with 35-54% for all psychiatric patients and 20% for the 
general population (see Adler et al., 1998; D'Souza & Markou, 2012). Nicotine has been shown 
to transiently ameliorate attention (Dépatie et al., 2002; Harris et al., 2004), working memory 
(Nuechterlein et al., 2004) and sensory gating (Adler et al., 1998; Olincy et al., 1998) deficits 
in schizophrenic patients, indicating a possible use of nicotine via smoking as a self-medication 
in these patients (Glassman, 1993; Kumari & Postma, 2005). By using the G72Tg mouse model 
of schizophrenia, we found that chronic nicotine administration was effective in restoring 
impaired prepulse inhibition, working memory, associative learning and social recognition in 
G72Tg mice further supporting the beneficial attributes of nicotine in modulating cognitive 
deficits symptoms of schizophrenia (Hambsch et al., 2014). Although the benefits of nicotine 
use in schizophrenia have been broadly studied, the neurobiology underlining this nicotine 
dependence-schizophrenia comorbidity remains unclear.  
There is emerging evidence suggesting that the central oxytocinergic system plays a 
key role in the psychopathology of both drug addiction, including nicotine dependence, and 
schizophrenia. Research into the underlying mechanisms of cognitive deficits associated with 
schizophrenia has revealed a key role of the oxytocinergic system, primarily due to its 
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modulatory role in social cognition (Stoop, 2012). In particular, intranasal oxytocin (OT) 
treatment in schizophrenic patients abolishes psychotic symptoms (Bujanow, 1974), reduces 
positive and negative symptoms of schizophrenia (Feifel et al., 2010) and improves social 
perception (Pedersen et al., 2011). Similarly, OT administration restores social behavior which 
is profoundly impaired in animal models of schizophrenia (Lee et al., 2007). Previous studies 
have also identified reduced plasma OT levels in schizophrenic patients (Walss-Bass et al., 
2013), suggesting a possible dysregulation of the oxytocinergic system in some schizophrenia-
related symptomology. Indeed, higher OT levels in the blood were directly correlated with 
reduced schizophrenia-related symptoms in women (Sasayama et al., 2012). Several OT 
receptor (OTR) single nucleotide polymorphisms (SNPs) have been associated with increased 
severity of various schizophrenia-like symptoms. In particular, rs2254298, rs53576 or 
rs237885 SNPs on the otr gene have all been associated with severe psychopathology and 
negative symptoms of schizophrenia (Montag et al., 2012). Overall, these studies provide 
evidence that the oxytocinergic system is likely to be involved in the underlying 
psychopathology of schizophrenia.  
In addition to schizophrenia, the OT system has been also widely implicated in drug 
addiction processes. Specifically, chronic administration of drugs of abuse such as cocaine 
(Sarnyai et al., 1992; Georgiou et al., 2015a), methamphetamine (Zanos et al., 2014b; 
Georgiou et al., 2016), morphine (Zanos et al., 2014a), alcohol (Silva et al., 2002) and nicotine 
(Zanos et al., 2015) induce alterations in the central OTR system. Moreover, prenatal combined 
treatment with alcohol and nicotine decreased OT levels (McMurray et al., 2008) and increased 
OTR binding in the brain of rats (Williams et al., 2009). Acute intravenous administration of 
nicotine has been shown to decrease OT content in the pituitary of rats (Russell & Chaudhury, 
1972), and systemic administration of OT abolished physical somatic symptoms of nicotine 
withdrawal in rat (Manbeck et al., 2014) and reduced cigarette consumption in daily smokers 
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(Van Hedger et al., 2018). There is ample evidence clearly demonstrating that OT 
administration can modulate addiction related behaviors (McGregor & Bowen, 2012; Zanos et 
al., 2017) and can prevent relapse (Zanos et al., 2014a; Georgiou et al., 2015b) and thus has 
been proposed as a novel treatment for drug addiction. Interestingly, due to the anxiolytic, 
antidepressant and prosocial properties of OT, there is particular interest in its potential efficacy 
in the treatment of mental health disorder comorbidities including addiction-depression 
comorbidity (Zanos et al., 2017). Nonetheless, the role of OT in addiction-schizophrenia 
comorbidity remains unclear.   
Genome-wide association studies have implicated the G72/G30 gene locus (13q32-
q34) in susceptibility to schizophrenia (for review see Drews et al., 2012). G72 is a primate-
specific gene encoding the G72 protein in humans, and a truncated form in non-human 
primates. The G72 protein deactivates D-amino acid oxidase (DAOA) (Sacchi et al., 2008) 
thus preventing the oxidation of D-serine, an activator of the NMDA glutamate receptor 
(Chumakov et al., 2002) by decreasing the glutamatergic signalling. Abnormalities in the 
glutamatergic system, particularly in the cortical regions of the brain, have been implicated in 
the pathophysiology of schizophrenia (for reviews see Olney & Farber, 1995; Adell et al., 
2012), and transgenic mice with decreased NMDA receptor levels display schizophrenia-like 
behavioral abnormalities (Mohn et al., 1999). 
To investigate the possible involvement of OT in the mechanism underlining nicotine 
dependence and schizophrenia comorbidity, we aimed to assess if OTR levels were 
dysregulated in the brains of the G72Tg mouse model of schizophrenia and whether chronic 
nicotine treatment was able to modulate such dysregulation. 
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METHODS 
Animals and chronic nicotine administration paradigm 
 WT and heterozygous G72Tg transgenic CD-1 mice were originally generated by Otte 
et. al., (2009), at the University of Bonn. The animals were individually housed, 12:12 h 
reversed light/dark-cycle, in a temperature-controlled environment with food and water 
available ad libidum. Female mice (16 G72Tg and 17 WT littermates, total 33 animals, 10-12 
weeks old, 31-35 grams) were administered with chronic saline (8 G72Tg, 10 WT) or (-)-
Nicotine hydrogen tartrate salt (24 mg/kg/day; Sigma, St. Louis, MO, USA) delivered in 
physiological saline (0.9%) (8 G72Tg and 7 WT) for 14 days using Alzet® osmotic minipumps 
(Charles River GMbH, Kißlegg, Germany). This treatment protocol is known to produce 
nicotine plasma concentrations similar to those found in human smokers (Hambsch et al., 
2014). For minipump implantation, mice were anaesthetised using isoflurane/oxygen vapor 
mixture (3.5%–4.5%; Isoflo, Abbott Laboratories Ltd, UK). 0.2 mg/kg meloxicam (i.m). was 
used for analgesia. A single incision along the midline of the back of each animal was made 
and osmotic mini-pumps were placed in parallel position to the spine. The flow operator was 
pointing away from the incision site. Nicotine was delivered for a period of 14 days at the daily 
dose of 7.8 mg/kg (free-base weight), at a rate of 0.5 μl per hour. Since the behavioral effects 
of nicotine were more pronounced in female compared with male mice in this transgenic line 
(Hambsch et al., 2014) autoradiography was undertaken only in the brains of female mice. 
Animal work was carried out in accordance with German and EU regulations (European 
Communities Council Directive 2010/63EU) and was approved by local authorities (University 
of Bonn animal experimentation ethics committee file-no.87-51.04.2010.A070). The animal 
work was reported according to ARRIVE guidelines. For checklist assessing compliance to 
ARRIVE guidelines please see Supplementary Table. 1. 
Quantitative receptor autoradiography 
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Following 14 days of chronic nicotine treatment, mice were killed by cervical 
dislocation, brains were removed and frozen using isopentane solution (-20oC) for 30 sec and 
stored at -80 oC, until use. Adjacent 20 μm coronal brain sections were cut at 300 μm intervals 
from fore to hind brain (complete mapping) at -21 °C using a cryostat apparatus and thaw 
mounted onto ice-cold microscope slides. Quantitative autoradiography was performed on 
brain sections from chronic saline- and nicotine-treated WT and G72Tg mice in accordance 
with previously described methods (Jarrett et al., 2006; Zanos et al., 2014b). Total binding was 
determined by incubating sections with 50 pM 125I-ornithine vasotocin (OVTA) for 1 hour in 
an incubation buffer medium containing 50mM Tris-HCl, 10mM MgCl2, 1mM 
ethylenediaminetetraacetic acid (EDTA), 0.1 % w/v bovine serum albumin, and 0.05 % w/v 
bacitracin (Sigma-Aldrich, Poole, UK, pH 7.4 at room temperature). Adjacent sections were 
incubated with [125I]-OVTA (50 pM) in the presence of 50μM unlabelled (Thr4,Gly7)-oxytocin 
(Bachem, Germany), to determine non-specific binding (NSB). Slides were apposed to Kodak 
MR-1 films (Sigma-Aldrich, UK) in Hypercassettes with autoradiographic [14C] microscales 
of known radioactive concentration (GE Healthcare Life Sciences, Amersham, U.K.) for 3 
days. Films were developed in a 50% Kodak D19 developer solution (Sigma-Aldrich, Poole, 
UK) and analyzed using MCID image analyzer (Image Research, Ontario, Canada) as 
previously described by Kitchen et al. (1997). Brain structures were identified by reference to 
the mouse atlas of Franklin and Paxinos (2001).  
Statistical analysis 
Data are presented as mean ± SEM and were analysed using GraphPad Prizm software. 
The same regions were analysed in all mice but binding in some regions could not be analysed 
due to either damage to the brains or sections thus the sample size change between brain 
regions. For the determination of differences in OTR binding between the different treatment 
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groups, two-way ANOVA for each brain region were performed with factors ‘treatment’ and 
‘genotype’, followed by Holm-Sidak post-hoc test. Statistical significance was set to p≤0.05. 
 
RESULTS 
Effect of nicotine on oxytocin binding in WT and G72Tg mice 
High levels of OTR binding (2.85–4.99 fmol/mg tissue) were found in the olfactory nuclei, 
piriform/endopiriform cortices, lateral septum and amygdala; medium binding levels (0.96–
2.54 fmol/mg tissue) in the cingulate cortex, olfactory tubercle, medial septum, ventral limb of 
the diagonal band of Broca and hypothalamus; and low levels (0.24–0.57 fmol/mg tissue) in 
the striatal areas (i.e., nucleus accumbens and caudate putamen), as well as the thalamus 
(Figures 1 and 2). 
A significant treatment effect was observed in the medial septum (F(1, 24) = 4.01; p =0.05) (Table 
1; Fig. 2). Holm-Sidak post-hoc analysis showed a near significant increase in OTR binding in 
saline-treated G72Tg compared with the saline-treated WT mice (p = 0.09), which returned to 
control levels following chronic nicotine administration (saline treated G72Tg vs nicotine 
treated G72Tg; p <0.05; n = 6-8/group). In the nucleus accumbens, two way ANOVA revealed 
a significant genotype effect (F(1, 24) = 4.01; p = 0.05) but no treatment or treatment x genotype 
interaction effects (p>0.05).  
A significant genotype x treatment interaction effect was detected in the cingulate cortex (F(1, 
23) = 4.86; p =0.04) and the central amygdala (F(1, 24) = 15.05; p = 0.0007) with a near significant 
interaction effect observed in the anterior olfactory nucleus (medial) (F(1, 19) = 3.66; p = 0.07). 
No individual treatment or genotype effects were observed in these regions (p>0.05). Holm-
Sidak post-hoc analysis showed near significantly higher levels of OTR in the anterior olfactory 
nucleus (medial) (p=0.08) and significantly higher levels of OTR in the cingulate cortex 
(p<0.05) and the central amygdala (p<0.05) of saline treated G72Tg mice compared with WT. 
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Chronic nicotine treatment restored OTR levels back to control WT saline levels in G72Tg 
mice in all these regions (p<0.05, saline-treated G72Tg compared with nicotine-treated G72Tg 
mice; p>0.05, saline WT compared to nicotine G72Tg). Interestingly, chronic administration 
of nicotine increased OTR binding only in the central amygdala of WT compared with saline 
WT controls (p <0.01; n = 6–8/group). This nicotine induced upregulation was not observed in 
G72Tg mice (p>0.05). 
No other genotype, treatment or genotype x treatment interaction effects were observed in any 
other regions analysed (p>0.05). 
DISCUSSION 
In the present study, we found increased OTR binding in the cingulate cortex and central 
amygdaloid nucleus in the brain of a G72Tg mouse model of schizophrenia compared with 
WT; this effect was reversed by chronic nicotine administration. In addition, we showed an 
effect of chronic nicotine administration in increasing OTR binding in the central amygdala of 
WT mice in line with our previous findings (Zanos et al., 2015). This nicotine-induced 
upregulation was absent in G72Tg mice. 
Higher rates of smoking among schizophrenics exist compared with the general 
population and schizophrenic patients tend to be heavier smokers, obtaining higher levels of 
nicotine per cigarette (de Leon & Diaz, 2005). We have previously shown, using the same 
administration paradigm, that chronic nicotine treatment was able to reverse several cognitive 
deficits in the G72Tg mouse model of schizophrenia (Hambsch et al., 2014) supporting the 
concept that schizophrenic patients may use nicotine from cigarettes to self-medicate some of 
the symptoms of schizophrenia (Glassman, 1993; Kumari & Postma, 2005). More specifically, 
we showed that chronic nicotine administration was effective in restoring impaired prepulse 
inhibition, working memory, associative learning and social recognition in G72Tg mice, 
further supporting the beneficial attributes of nicotine in modulating cognitive deficits 
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symptoms of schizophrenia (Hambsch et al., 2014). However, the mechanisms underlying the 
beneficial effects of nicotine treatment for alleviating negative symptoms of schizophrenia, 
including impaired cognition, are still not well understood. Since oxytocin has been implicated 
in the different aspects of cognition (Lee et al., 2015; Crespi, 2016) and social information 
processing (Freeman et al., 2014a; Freeman et al., 2014b), both of which are disrupted in 
schizophrenic patients (Bowie & Harvey, 2006), we assessed the regulation of the 
oxytocinergic system in the brains of the G72Tg mouse model of schizophrenia.  
We decided to focus this study on female G72Tg mice based on our previous 
observations indicating that the restorative effect of nicotine on pre-pulse inhibition deficits 
and certain cognitive deficits in G72Tg mice are more pronounced in female mice compared 
with male mice (Hambsch et al., 2014). This is consistent with the gender differences observed 
in characteristics and behaviours of smokers diagnosed with psychosis (Filia et al., 2014). 
Thus, in order to elucidate corresponding molecular mechanisms underlying the beneficial 
effects of nicotine in G72Tg mice, we focused our OT receptor autoradiographic study on 
female WT and G72Tg mice. 
Here we demonstrate a dysregulation of OTR density in G72Tg mice in brain regions 
associated with social cognition and social processing. Indeed, the upregulation of OTR 
observed in the G72Tg mouse model of schizophrenia were localized in the cingulate cortex 
and amygdala, regions that have been shown to mediate the effects of OT on social cognition 
and social processing (Zink & Meyer-Lindenberg, 2012). In addition, a neuronal interaction 
between the cingulate cortex and amygdala has been shown to mediate fear processing 
(Williams et al., 2006), which is also impaired in schizophrenics (Michalopoulou et al., 2008), 
suggesting that oxytocinergic dysregulation within these brain circuits might underlie some of 
the negative symptoms of schizophrenia. Increases in OTR binding were also observed in the 
medial septum and nucleus accumbens of the G72Tg mouse model of schizophrenia in the 
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present study but this upregulation did not quite reach statistical significance. Notably, deep 
brain stimulation specifically in these two brain regions was shown to alleviate psychotic 
symptoms in rats (Ma & Leung, 2014), suggesting that changes in the OTR system in both 
these brain areas might be involved in psychosis observed in schizophrenic patients; however 
the exact role of OT in the modulation of such behaviors requires further investigation.  
Although the molecular mechanism underpinning the upregulation of OTR in certain 
brain regions of G72Tg mice cannot be determined from this study, it is likely that this may be 
driven by alterations in central OT levels. An increase in OT peptide or repeated activation of 
OTRs is known to cause a rapid desensitisation of OTRs and consequently decreases receptor 
binding in cells (Evans et al., 1997) and brains of animals (Peters et al., 2014; Rae et al., 2018) 
Rae et al., 2018; Peters et al., ). Several studies have reported low levels of central OT go hand 
in hand with high OTR density in the brain of the same animals (Lee et al., 2007; Zanos et al., 
2014a). Interestingly, this central oxytocinergic dysregulation has been shown to be 
concomitant with the emergence of social deficit and emotional impairment, behaviors which 
were reversed by administration of the OT or OT analogues (Zanos et al. 2014; (Green & 
Leitman, 2008), pointing towards a causal relationship between central oxytocinergic 
dysregulation and socio-emotional impairment. Therefore, we can postulate that the increased 
OTR binding observed in the present study is caused by a reduction in OT peptide levels in the 
brain as a compensatory neuroadaptive mechanism. This is in line with decreased plasma OT 
levels and hypothalamic OT mRNA levels found in schizophrenic patients (Walss-Bass et al., 
2013) and rodents (Lee et al., 2007) respectively, an effect which was concomitant with an 
increase in OTR binding in the central nucleus of the amygdala of a different rodent model of 
schizophrenia (Lee et al., 2007) Moreover, several studies have demonstrated beneficial effects 
of OT in treating social cognitive deficits in schizophrenic patients (Feifel & Shilling, 2010; 
Fischer-Shofty et al., 2013; see also Miyamoto et al., 2013a), further supporting the hypothesis 
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that dysregulated central oxytocinergic system may mediate some of the symptoms observed 
in schizophrenia. 
Interestingly, here we show that chronic nicotine treatment reverses the brain specific 
upregulated OTR observed in G72Tg mice clearly indicating that the dysregulated central OTR 
system is under the regulatory control of nicotine. Whether this regulatory effect of nicotine on 
the OTR system of G72Tg mice underlines the beneficial effect of nicotine on alleviating 
cognitive deficits experienced by schizophrenic patients cannot be determined from this study. 
Nonetheless the fact that these nicotine-induced oxytocinergic neuroadaptations are 
concomitant with a complete nicotine induced reversal of impaired prepulse inhibition, 
working memory, associative learning and social recognition detected in G72Tg mice 
(Hambsch et al., 2014) makes this hypothesis plausible. Interestingly, the effects of nicotine 
on attention performance (Mobascher et al., 2012) and working memory (Ernst et al., 2001) 
have been associated with an activation of the anterior cingulate cortex, supporting our 
hypothesis of an involvement of the OTR system in the cingulate cortex to underlie the 
beneficial effects of nicotine on schizophrenia. Moreover, we have demonstrated that chronic 
nicotine administration abolished increases in OTR binding within the medial septum of 
G72Tg mice, a region associated with social memory (Lukas et al., 2013). Given the key role 
of the septum in mediating the beneficial effects of nicotine on social cognition, which is 
impaired in schizophrenics (Beck et al., 2015), together with oxytocins’ cognitive enhancement 
properties (Zink & Meyer-Lindenberg, 2012),  it would be intriguing to suggest a possible role 
of the septal OT system in modulating the enhancement of social cognition by chronic nicotine 
administration in mouse model of schizophrenia. 
Although 125I-ornithine vasotocin (OVTA) used to label OTR in our study is highly 
selective antagonist for oxytocin receptors and has negligible affinity for vasopressin receptors 
(Elands et al., 1988), one cannot entirely exclude the possibility that OVTA binding may reveal 
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a small proportion of vasopressin receptors in addition to OTRs. In addition, due to the 
structural similarity of OT to the related neuropeptide vasopressin, and hence the cross-
reactivity of the latter to OTRs (Neumann & Landgraf, 2012), we cannot rule out the possibility 
that nicotine-induced increase in vasopressin release could also contribute to the normalization 
of the expression of OTRs in some of the brain regions of G72Tg mice. Indeed, there is some 
evidence that nicotine can also induce vasopressin secretion from the hypothalamus (Fuxe et 
al., 1983). 
Using the same G72Tg mouse model of schizophrenia, we have previously shown that 
chronic nicotine administration reversed increases in α7 nicotinic receptor binding within the 
cingulate cortex of G72Tg compared with WT mice. This is particularly important since 
adjunctive treatment with α7 nAChR agonists and OT is believed to be promising in the 
treatment of negative symptoms of schizophrenia, including psychotic symptoms and cognitive 
deficits (Miyamoto et al., 2013b). Therefore, an interaction between the oxytocinergic and 
nicotinic acetylcholine receptor systems might exist in the brain to mediate several of the 
negative symptoms of schizophrenia. This hypothesis warrants further investigation, especially 
in the light of the findings of Zaninetti et al., (2002), who showed that nicotinic agonists can 
directly increase excitability of OT magnocellular neurons. Additionally, nicotine 
administration was shown to directly induce a marked activation (85%) of the oxytocinergic 
neurons in the hypothalamus of rats (Mikkelsen et al., 2012), where 7 nicotinic acetylcholine 
receptors were shown to be expressed (Hatton & Yang, 2002), further supporting an interaction 
between these systems.  
Altogether, the current findings suggest the possibility that nicotine treatment improves 
at least some of the symptoms of schizophrenia via an oxytocinergic mechanism, thus 
supporting the self-medication hypothesis, that schizophrenic patients might smoke more than 
non-schizophrenic populations in an attempt to self-medicate distressing cognitive symptoms 
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(Kumari & Postma, 2005). While smoking is known to be harmful to health (The Health and 
Social Care Information Centre, 2012) and current guidelines recommend a variety of smoking 
cessation methods for people suffering from schizophrenia (NICE, 2015), traditional NRT 
and/or novel nicotine containing products such as electronic cigarettes may be useful not only 
for improving smoking cessation rates (Hickling et al., 2018), but also to treat some of the 
symptoms of schizophrenia. Interestingly, the beneficial effects of nicotine on cognitive 
behavior in G72Tg mice were observed following relatively high doses (24 mg kg−1 day−1, also 
used in the present study)-albeit within the range observed in smokers- but not at low dose 
(16 mg kg−1 day−1) of nicotine exposure (Hambsch et al., 2014), which is in line with the higher 
cigarette consumption and nicotine intake rate of schizophrenic patients compared with control 
smokers (Olincy et al., 1997) It is therefore possible that higher levels of nicotine are required 
to normalise the upregulated OTRs in G72Tg mice brains and hence alleviate some of the 
cognitive deficits in these animals, and may have implications on the dose of nicotine 
recommended for schizophrenic smokers undergoing nicotine containing smoking cessation 
methods. As there are safety concerns regarding very high doses of nicotine, a useful alternative 
may consist of an adjunctive treatment of OT which is known to also known to cause 
downregulation of OTRs in the brain (Peters et al., 2014) with “safer” doses of nicotine. Such 
targeted pharmacotherapies in this specific population warrants further investigation. 
In conclusion, the present study demonstrates that dysregulated OTRs in a mouse model 
of schizophrenia are under regulatory control of nicotine, suggesting a possible interaction 
between nAChR and OTR systems in the mechanism underlying nicotine dependence-
schizophrenia comorbidity. Whether there is a causal relationship between this regulatory 
control of nicotine and its beneficial effect in ameliorating cognitive symptoms of 
schizophrenia warrants further investigation.  
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Table 1. Two Way ANOVA factorial results  
Brain region Treatment Genotype Interaction Animal numbers
Anterior olfactory nucleus-lateral F(1, 18) = 0.82; p  = 0.38 F(1, 18) = 0.47; p  = 0.50 F(1, 18) = 0.71; p  = 0.41 n = 5-7
Anterior olfactory nucleus-ventral F(1, 19) = 0.002; p  = 0.96 F(1, 19) = 0.02; p  = 0.89 F(1, 19) = 2.28; p  = 0.15 n = 5-6
Anterior olfactory nucleus-mediall F(1, 19) = 2.54; p  = 0.13 F(1, 19) = 1.44; p  = 0.25 F(1, 19) = 3.66; p  = 0.07 n = 5-7
Cingulate cortex F(1, 23) = 2.23; p  = 0.15 F(1, 23) = 3.28; p  = 0.08 F(1, 23) = 4.86; p  = 0.04 * [% 14.88] n = 6-8
Piriform cortex F(1, 26) = 1.35; p  = 0.26 F(1, 26) = 0.78; p  = 0.39 F(1, 26) = 1.65; p  = 0.21 n = 6-9
Endopiriform cortex F(1, 24) = 0.33; p  = 0.57 F(1, 24) = 0.21; p  = 0.65 F(1, 24) = 0.88; p  = 0.36 n = 6-8
Olfactory tubercle F(1, 21) = 0.23; p  = 0.64 F(1, 21) = 0.007; p  = 0.93 F(1, 21) = 0.19; p  = 0.66 n = 4-8
Nucleus accumbens F(1, 24) = 0.13; p  = 0.72 F(1, 24) = 4.01; p  = 0.05 * [13.08%] F(1, 24) = 2.28; p  = 0.11 n = 6-8
Caudate putamen F(1, 25) = 2.00; p  = 0.17 F(1, 25) = 0.02; p  = 0.88 F(1, 25) = 0.10; p  = 0.76 n = 6-8
Lateral septum F(1, 25) = 0.09; p  = 0.77 F(1, 25) = 2.57; p  = 0.12 F(1, 25) = 1.72; p  = 0.20 n = 5-10
Medial septum F(1, 23) = 4.01; p  = 0.05 * [12.58%] F(1, 24) = 1.69; p  = 0.21 F(1, 24) = 3.00; p  = 0.09 n = 6-8
Ventral limb of the diagonal band of Broca F(1, 24) = 0.48; p  = 0.50 F(1, 24) = 1.66; p  = 0.21 F(1, 24) = 1.91; p  = 0.18 n = 6-8
Hippocampus F(1, 22) = 0.90; p  = 0.35 F(1, 22) = 1.76; p  = 0.20 F(1, 22) = 1.48; p  = 0.24 n = 5-9
Thalamus F(1, 21) = 0.003; p  = 0.96 F(1, 21) = 0.20; p  = 0.66 F(1, 21) = 0.27; p  = 0.61 n = 5-9
Hypothalamus F(1, 22) = 0.07; p  = 0.80 F(1, 22) = 0.86; p  = 0.36 F(1, 22) = 0.03; p  = 0.85 n = 5-9
Basolateral amygdala F(1, 21) = 0.02; p  = 0.88 F(1, 21) = 0.24; p  = 0.63 F(1, 21) = 0.15; p  = 0.70 n = 4-9
Basomedial amygdala F(1, 19) = 0.93; p  = 0.35 F(1, 19) = 0.31; p  = 0.58 F(1, 19) = 3.84; p  = 0.07 n = 4-8
Central amygdala F(1, 24) = 0.28; p  = 0.60 F(1, 24) = 0.03; p  = 0.87 F(1, 24) = 15.05; p  = 0.0007 *** [37.88%] n = 6-8
*p ≤0.05; ***p ≤0.001
% of total variation (eta squared)  is included in brackets   
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FIGURE LEGENDS 
Figure 1: Representative autoradiograms of [125I]OVTA binding following chronic saline or 
nicotine treatment in wild type (WT) and G72 transgenic (G72Tg) mice. Computer enhanced 
colour autoradiograms of 50 pmol [125I]-ornithine vasotocin analogue ([125I]OVTA) binding to 
oxytocin receptors (OTR) in coronal brain sections of WT and G72Tg mice treated with 
chronic saline or nicotine (24 mg/kg/day) via subcutaneous minipumps for 14 days. Coronal 
brain sections are represented at the level of the olfactory nuclei (row 1; Bregma 2.46 mm), 
striatum (row 2; Bregma mm), septum (row 3; Bregma 0.86 mm). Adjacent sections were 
incubated with 50 μM oxytocin to determine non-specific binding (NSB). Binding levels are 
represented using a pseudo-color interpretation of black and white film images in fmol/mg of 
tissue equivalent.  
 
Figure 2: Quantitative [125I]OVTA binding in saline- and nicotine-treated wild type (WT) 
and G72 transgenic (G72Tg) mice. Brain sections from WT and G72Tg mice treated with 
chronic saline (SAL) or nicotine (NIC; 24 mg/kg/day) via subcutaneous minipumps for 14 days 
were bound with [125I]OVTA to determine OTR binding levels in the (A-C) anterior olfactory 
nuclei, (D) cingulate, (E) piriform and (F) endopiriform cortices, (G) olfactory tubercle, (H) 
nucleus accumbens, (I) caudate putamen, (J) lateral and (K) medial septum, (L) ventral limb 
of the diagonal band of Broca, (M) hippocampus, (N) thalamus, (O) hypothalamus, (P) 
basolateral, (Q) basomedial and (R) central amygdala. Data are presented as mean ± standard 
error of the mean. * p<0.05; ** p<0.01 (n = 4-10/group). 
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